Previous 10 | Next 10 |
Unity Biotechnology (NASDAQ: UBX ): Q4 GAAP EPS of -$0.53 misses by $0.10. More news on: Unity Biotechnology, Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO, March 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported business highlights and financial results for the fourth ...
SAN FRANCISCO, March 04, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard, chairman and chief e...
SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. [Nasdaq: UBX], please note that in the first paragraph of the release, financial results will be reported before Nasdaq market open, not after...
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [Nasdaq: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report financial results for the fourth quarter and full year e...
Deals and Financings Apollomics, a Foster City-Hangzhou innovative oncology biopharma, raised $100 million in a Series B financing, led by CMB International, a subsidiary of China Merchants Bank. Previously, Apollomics was known as CBT, the drug development spin-out of cancer CRO Crown Bio...
Unity Biotechnology (NASDAQ: UBX ): Q3 GAAP EPS of -$0.45. More news on: Unity Biotechnology, Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported third quarter 2018 financial results. "...
SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the third quarter ended Septe...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this n...
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...